AU2022285758A1 - Substituted tetrahydrofuran analogs as modulators of sodium channels - Google Patents

Substituted tetrahydrofuran analogs as modulators of sodium channels Download PDF

Info

Publication number
AU2022285758A1
AU2022285758A1 AU2022285758A AU2022285758A AU2022285758A1 AU 2022285758 A1 AU2022285758 A1 AU 2022285758A1 AU 2022285758 A AU2022285758 A AU 2022285758A AU 2022285758 A AU2022285758 A AU 2022285758A AU 2022285758 A1 AU2022285758 A1 AU 2022285758A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
pain
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022285758A
Other languages
English (en)
Inventor
Nadia M. Ahmad
James Robert AUSTIN
Elizabeth Mary BECK
Lidio Marx Carvalho Meireles
Ewa Iwona CHUDYK
Steven John Durrant
Gorka ETXEBARRIA JARDI
Damien Fraysse
Bhairavi GALAN
Stephen Michael GEDDIS
Sara S. Hadida Ruah
Dennis James Hurley
Reece JACQUES
Alexander KINTZER
Ronald Marcellus KNEGTEL
James Jun Bon Mui
Timothy Donald Neubert
Kiri NORTH
Joanne Louise Pinder
Joseph Pontillo
Robert PULLIN
Yvonne Schmidt
David Matthew Shaw
Sarah Skerratt
Bruno Artur SOUSA
Dean Stamos
Pierre-Henri Storck
Stephen Andrew Thomson
Anisa Nizarali Virani
Christopher Wray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2022285758A1 publication Critical patent/AU2022285758A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Interface Circuits In Exchanges (AREA)
  • Amplifiers (AREA)
AU2022285758A 2021-06-04 2022-06-03 Substituted tetrahydrofuran analogs as modulators of sodium channels Pending AU2022285758A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163197199P 2021-06-04 2021-06-04
US63/197,199 2021-06-04
PCT/US2022/032196 WO2022256676A1 (en) 2021-06-04 2022-06-03 Substituted tetrahydrofuran analogs as modulators of sodium channels

Publications (1)

Publication Number Publication Date
AU2022285758A1 true AU2022285758A1 (en) 2023-11-30

Family

ID=82358650

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022285758A Pending AU2022285758A1 (en) 2021-06-04 2022-06-03 Substituted tetrahydrofuran analogs as modulators of sodium channels

Country Status (7)

Country Link
US (1) US20250213555A1 (enExample)
EP (1) EP4347583A1 (enExample)
JP (1) JP2024522293A (enExample)
CN (1) CN117794918A (enExample)
AU (1) AU2022285758A1 (enExample)
CA (1) CA3221938A1 (enExample)
WO (1) WO2022256676A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250052383A (ko) * 2022-08-24 2025-04-18 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 헤테로시클릭계 화합물, 이의 제조 방법 및 이의 의학적 응용
CN119731169A (zh) * 2022-08-28 2025-03-28 上海汇伦医药股份有限公司 一种钠通道调节剂及其应用
EP4647430A4 (en) * 2023-01-06 2026-03-11 Haisco Pharmaceutical Group Co Ltd Tetrahydrothiophene derivative and its use in medicine
WO2024188367A1 (zh) * 2023-03-10 2024-09-19 西藏海思科制药有限公司 一种四氢呋喃衍生物及其在医药上的应用
WO2024217557A1 (zh) * 2023-04-19 2024-10-24 武汉人福创新药物研发中心有限公司 取代的四氢呋喃作为Nav1.8抑制剂
WO2024217528A1 (zh) * 2023-04-20 2024-10-24 西藏海思科制药有限公司 一种杂环化合物及其在医药上的应用
CN119371405A (zh) 2023-07-26 2025-01-28 上海闻耐医药科技有限公司 多取代吡咯烷类衍生物、其制备方法及用途
WO2025090480A1 (en) * 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090465A1 (en) * 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AR134204A1 (es) * 2023-11-01 2025-12-10 Insilico Medicine Ip Ltd Nuevos compuestos como moduladores de los canales de sodio y usos de los mismos
WO2025092922A1 (en) * 2023-11-02 2025-05-08 Iongen Therapeutics Co., Ltd. Compounds, compositions and methods thereof
WO2025108234A1 (zh) * 2023-11-20 2025-05-30 四川科伦药物研究院有限公司 化合物、其制备方法及用途
WO2025108301A1 (zh) * 2023-11-21 2025-05-30 武汉熙瑞医药科技有限公司 一种含呋喃环的化合物、其药物组合物及其应用
WO2025131099A1 (zh) * 2023-12-21 2025-06-26 武汉熙瑞医药科技有限公司 一种含苯环的多环化合物、其药物组合物及其应用
CN120208958A (zh) * 2023-12-26 2025-06-27 南京清普生物科技有限公司 一种新型钠通道调节剂
WO2025162194A1 (zh) * 2024-01-31 2025-08-07 上海汇伦医药股份有限公司 钠通道调节剂新化合物及其应用
TW202545937A (zh) * 2024-02-01 2025-12-01 大陸商海思科醫藥集團股份有限公司 含硫雜環衍生物及其在醫藥上的應用
WO2025168043A1 (zh) * 2024-02-08 2025-08-14 上海枢境生物科技有限公司 并环类衍生物、制备方法及其用途
CN120774914A (zh) * 2024-04-03 2025-10-14 武汉人福创新药物研发中心有限公司 作为Nav1.8抑制剂的四氢呋喃吡啶酮类化合物
WO2025218764A1 (zh) * 2024-04-19 2025-10-23 广州市联瑞制药有限公司 作为电压门控钠通道抑制剂的化合物及其应用
WO2025223430A1 (zh) * 2024-04-22 2025-10-30 晶新医药研发（上海）有限公司 一种五元杂环类化合物、药物组合物及其应用
WO2025223429A1 (zh) * 2024-04-22 2025-10-30 晶新医药研发（上海）有限公司 一种五元杂环类化合物、药物组合物及其应用
TW202543620A (zh) * 2024-04-22 2025-11-16 大陸商上海青煜醫藥科技有限公司 一種五元雜環類化合物、藥物組合物及其應用
CN118388466A (zh) * 2024-04-23 2024-07-26 安润医药科技（苏州）有限公司 作钠通道调节剂的酰胺衍生物及其用途
WO2025252109A1 (zh) * 2024-06-04 2025-12-11 成都苑东生物制药股份有限公司 一种取代四氢呋喃类衍生物、其制备方法及用途
CN121085873A (zh) * 2024-06-07 2025-12-09 济川药业集团有限公司 一种用作电压门控钠通道抑制剂的杂环类化合物及其药物组合物、药物制剂和应用
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
CN118772124A (zh) * 2024-07-01 2024-10-15 山东福长药业有限公司 一种Suzetrigine的制备方法
CN121591707A (zh) * 2024-08-15 2026-03-03 思路迪生物医药(上海)有限公司 选择性钠通道调节剂及其制备和应用
CN119613390B (zh) * 2024-11-11 2025-10-28 广州楷石医药有限公司 氘代四氢呋喃类NaV1.8抑制剂及其用途
CN119143737B (zh) * 2024-11-18 2025-07-18 嘉兴安帝康生物科技有限公司 四氢呋喃甲酰胺类钠通道调节剂及其在医药上的应用
CN119285621B (zh) * 2024-12-13 2025-07-18 嘉兴安帝康生物科技有限公司 作为钠通道调节剂的四氢呋喃甲酰胺类化合物及其在医药上的应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
ES2234451T1 (es) 2001-11-14 2005-07-01 Teva Pharmaceutical Industries Ltd. Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
AU2005266090A1 (en) 2004-07-23 2006-02-02 Pfizer Inc. Pyridine derivatives
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
MX2011006904A (es) 2008-12-26 2011-07-20 Dainippon Sumitomo Pharma Co Compuesto heterociclico biciclico novedoso.
CA2760946C (en) 2009-05-07 2019-06-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
KR101923367B1 (ko) 2011-02-02 2018-12-04 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
CA2850925C (en) 2011-10-26 2017-01-10 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
US9012443B2 (en) 2011-12-07 2015-04-21 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
NZ627259A (en) 2012-01-16 2016-12-23 Vertex Pharma Pyran-spirocyclic piperidine amides as modulators of ion channels
JP6002785B2 (ja) 2012-02-03 2016-10-05 ファイザー・インク ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
US20140211173A1 (en) 2013-01-30 2014-07-31 3M Innovative Properties Company Optical projection subsystem
CA2898653C (en) 2013-01-31 2021-09-28 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
RS56015B1 (sr) 2013-01-31 2017-09-29 Vertex Pharma Piridon amidi kao modulatori natrijumovih kanala
RU2683788C2 (ru) 2013-01-31 2019-04-02 Вертекс Фармасьютикалз Инкорпорейтед Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
UA119147C2 (uk) 2013-07-19 2019-05-10 Вертекс Фармасьютікалз Інкорпорейтед Сульфонаміди як модулятори натрієвих каналів
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
EA032928B1 (ru) 2015-03-02 2019-08-30 Эмджен Инк. Бициклические кетосульфонамидные соединения
ES2895155T3 (es) 2015-09-30 2022-02-17 Siteone Therapeutics Inc Saxitoxinas modificadas en 11,13 para el tratamiento del dolor
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CN110831945B (zh) 2017-03-29 2023-08-08 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
EP3625214B1 (en) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
AU2019302534B2 (en) 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
CA3105657A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
US12344595B2 (en) 2018-11-02 2025-07-01 Merck Sharp & Dohme Llc 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors
JP7288051B2 (ja) * 2018-11-02 2023-06-06 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害薬としての２－アミノ－Ｎ－ヘテロアリール－ニコチンアミド類
EP3891157A4 (en) 2018-12-05 2022-08-31 Merck Sharp & Dohme Corp. 4-AMINO- OR 4-ALKOXY-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATE SODIUM CHANNELS
US20220073471A1 (en) 2019-01-04 2022-03-10 Jiangsu Hengrui Medicine Co., Ltd. 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
TW202043200A (zh) 2019-01-25 2020-12-01 大陸商江蘇恆瑞醫藥股份有限公司 ２－側氧基－１，２－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
MX2021015605A (es) 2019-06-27 2022-02-16 Glaxosmithkline Ip Dev Ltd Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8.
CN112300051A (zh) 2019-07-31 2021-02-02 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN112300069A (zh) 2019-07-31 2021-02-02 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
WO2021032074A1 (zh) 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CN112390745B (zh) 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
CN112441969A (zh) 2019-08-30 2021-03-05 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
BR112022004495A8 (pt) 2019-09-12 2023-04-18 Jiangxi Jemincare Group Co Ltd Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
CN111217776A (zh) 2020-01-19 2020-06-02 中国人民解放军军事科学院军事医学研究院 含苯并杂环结构的酰胺衍生物、组合物和应用
CA3183948A1 (en) 2020-06-10 2021-12-16 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
US11802122B2 (en) 2020-06-17 2023-10-31 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors
US12516046B2 (en) 2020-06-17 2026-01-06 Merck Sharp & Dohme Llc 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors
CN115697327A (zh) 2020-06-17 2023-02-03 默沙东有限责任公司 作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺
EP4196482B1 (en) 2020-08-14 2025-10-01 SiteOne Therapeutics, Inc. Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
WO2022037647A1 (zh) 2020-08-19 2022-02-24 江苏恒瑞医药股份有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
TW202214259A (zh) 2020-08-19 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種選擇性ＮａＶ抑制劑的前藥及其晶型
CN111808019B (zh) 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN112225695B (zh) 2020-12-15 2021-03-02 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途
CN112457294B (zh) 2021-01-27 2021-06-04 上海济煜医药科技有限公司 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途
AU2022283934A1 (en) * 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels

Also Published As

Publication number Publication date
JP2024522293A (ja) 2024-06-13
CA3221938A1 (en) 2022-12-08
US20250213555A1 (en) 2025-07-03
WO2022256676A1 (en) 2022-12-08
CN117794918A (zh) 2024-03-29
EP4347583A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
EP4347031B1 (en) N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US20250213555A1 (en) Substituted tetrahydrofuran analogs as modulators of sodium channels
US11919887B2 (en) Substituted tetrahydrofurans as modulators of sodium channels
US20240400544A1 (en) N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
US20240294512A1 (en) Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
AU2022283934A1 (en) Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
AU2024367861A1 (en) Heteroaryl compounds for the treatment of pain
WO2025090480A1 (en) Heteroaryl compounds for the treatment of pain
OA21895A (en) N-(HydroxyalkyI (Hetero) Aryl) Tetrahydrofuran carboxamides as modulators of sodium channels.
EA051527B1 (ru) N-(гидроксиалкил(гетеро)арил)тетрагидрофуранкарбоксамиды в качестве модуляторов натриевых каналов
HK40080163A (en) Substituted tetrahydrofurans as modulators of sodium channels
HK40080163B (en) Substituted tetrahydrofurans as modulators of sodium channels